共查询到5条相似文献，搜索用时 4 毫秒
1.
Paul K. Whelton Robert M. Carey Wilbert S. Aronow Donald E. Casey Karen J. Collins Cheryl Dennison Himmelfarb Sondra M. DePalma Samuel Gidding Kenneth A. Jamerson Daniel W. Jones Eric J. MacLaughlin Paul Muntner Bruce Ovbiagele Sidney C. Smith Crystal C. Spencer Randall S. Stafford Sandra J. Taler Randal J. Thomas Jackson T. Wright 《Journal of the American Society of Hypertension》2018,12(8):579.e1-579.e73
2.
David M. Reboussin Norrina B. Allen Michael E. Griswold Eliseo Guallar Yuling Hong Daniel T. Lackland Edgar R. Miller Tamar Polonsky Angela M. Thompson-Paul Suma Vupputuri 《Journal of the American College of Cardiology》2018,71(19):2176-2198
Objective
To review the literature systematically and perform meta-analyses to address these questions: 1) Is there evidence that self-measured blood pressure (BP) without other augmentation is superior to office-based measurement of BP for achieving better BP control or for preventing adverse clinical outcomes that are related to elevated BP? 2) What is the optimal target for BP lowering during antihypertensive therapy in adults? 3) In adults with hypertension, how do various antihypertensive drug classes differ in their benefits and harms compared with each other as first-line therapy?Methods
Electronic literature searches were performed by Doctor Evidence, a global medical evidence software and services company, across PubMed and EMBASE from 1966 to 2015 using key words and relevant subject headings for randomized controlled trials that met eligibility criteria defined for each question. We performed analyses using traditional frequentist statistical and Bayesian approaches, including random-effects Bayesian network meta-analyses.Results
Our results suggest that: 1) There is a modest but significant improvement in systolic BP in randomized controlled trials of self-measured BP versus usual care at 6 but not 12 months, and for selected patients and their providers self-measured BP may be a helpful adjunct to routine office care. 2) systolic BP lowering to a target of <130 mm Hg may reduce the risk of several important outcomes including risk of myocardial infarction, stroke, heart failure, and major cardiovascular events. No class of medications (i.e., angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, calcium channel blockers, or beta blockers) was significantly better than thiazides and thiazide-like diuretics as a first-line therapy for any outcome. 相似文献3.
Paul K. Whelton Robert M. Carey Wilbert S. Aronow Donald E. Casey Karen J. Collins Cheryl Dennison Himmelfarb Sondra M. DePalma Samuel Gidding Kenneth A. Jamerson Daniel W. Jones Eric J. MacLaughlin Paul Muntner Bruce Ovbiagele Sidney C. Smith Crystal C. Spencer Randall S. Stafford Sandra J. Taler Randal J. Thomas Jackson T. Wright 《Journal of the American College of Cardiology》2018,71(19):2199-2269
4.
Scott M. Grundy Neil J. Stone Alison L. Bailey Craig Beam Kim K. Birtcher Roger S. Blumenthal Lynne T. Braun Sarah de Ferranti Joseph Faiella-Tommasino Daniel E. Forman Ronald Goldberg Paul A. Heidenreich Mark A. Hlatky Daniel W. Jones Donald Lloyd-Jones Nuria Lopez-Pajares Chiadi E. Ndumele Carl E. Orringer Joseph Yeboah 《Journal of the American College of Cardiology》2019,73(24):3168-3209
5.
Paul Muntner Robert M. Carey Samuel Gidding Daniel W. Jones Sandra J. Taler Jackson T. Wright Paul K. Whelton 《Journal of the American College of Cardiology》2018,71(2):109-118